LOCAL VASCULAR ADMINISTRATION OF ETOPOSIDO IN COMBINATION WITH RAPAMYCIN TO PREVENT RESISTANCE AFTER VASCULAR INJURY.

摘要

A medical device comprising: an implantable structure; and a basecoat matrix, which includes a combination of rapamycin and a cytostatic glycoside, in therapeutic doses, incorporated into a first polymeric material comprising a fluoropolymer, the basecoat matrix being fixed to the surface of the implantable medical device. for the treatment of restenosis after vascular injury; a topcoat, which includes a second polymeric material comprising an acrylic polymer, fixed to the basecoat matrix to control the elution rate of rapamycin and cytostatic glycoside; wherein the second polymeric material is incompatible with the first polymeric material, thus creating both a physical barrier and a chemical barrier to the elution of rapamycin and cytostatic glycoside.